Collectively, our results provide a rationale for the use of IGF-targeting strategies for the reprogramming of innate immune response cells from a tumor-promoting to a tumor-inhibiting phenotype, thereby enhancing their anti-cancer activity. Here, IGF1 is linked to cancer.